Despite the wide range of treatment options available, metastatic non-small-cell lung cancer (NSCLC) remains a major cause of cancer-related death. For patients with metastatic (EGFR- and ALK-negative/unknown) NSCLC, chemotherapy is still a mainstay of treatment. However, immune checkpoint inhibitors (Opdivo, Keytruda, and most recently Tecentriq) are revolutionizing the treatment algorithm for this subpopulation. As this market segment continues to evolve at a rapid pace, drug manufacturers must understand the unmet needs associated with the treatment of metastatic NSCLC to identify the opportunities for drug development. We focus on this commercially important subpopulation and assess how current therapies perform on key drug attributes and how these attributes affect medical oncologists’ prescribing decisions. We identify potential hidden opportunities and which emerging therapies (if any) could capitalize upon them. Furthermore, we use conjoint analysis to determine attribute and price trade-offs that surveyed medical oncologists are willing to make when considering treatment options for metastatic NSCLC and simulate the share of preference and likelihood to prescribe of different target product profiles.

Questions Answered:

  • What are the treatment drivers and goals for metastatic (EGFR- and ALK-negative/unknown) NSCLC?
  • What attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for metastatic (EGFR- and ALK-negative/unknown) NSCLC?
  • What are the prevailing areas of unmet need and opportunity in metastatic (EGFR- and ALK-negative/unknown) NSCLC?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new metastatic (EGFR- and ALK-negative/unknown) NSCLC drug?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in December 2016.

Key companies: Bristol-Myers Squibb, Merck & Co., Eli Lilly & Co., Roche/Genentech

Key drugs: Opdivo, Keytruda, Alimta, Avastin

Table of contents

  • Detailed, Expanded Analysis: EGFR- and ALK-Negative or unknown NSCLC (US/EU)
    • Key Updates
      • December 2017
      • September 2017
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Nonclinical Attributes
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Nonclinical Factors
      • Physician Rating of Treatment Drivers and Goals in Metastatic (EGFR- and ALK-Negative/Unknown) NSCLC
        • Efficacy
        • Safety and Tolerability
        • Nonclinical Factors
      • Stated vs. Derived Importance of Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Nonclinical Factors
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Metastatic (EGFR- and ALK-Negative/Unknown) NSCLC
        • Efficacy
        • Safety and Tolerability
        • Nonclinical Factors
      • Unmet Need in Metastatic (EGFR- and ALK-Negative/Unknown) NSCLC and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Metastatic (EGFR- and ALK-Negative/Unknown) NSCLC Market and Emerging Therapy Insights
        • Opportunity: A New Therapy That Offers Substantial Improvement in Overall Survival 
        • Opportunity: A New Therapy That Improves Progression-Free Survival
        • Opportunity: A New Therapy with Improved Duration of Response
        • Opportunity: A Novel Biomarker-Driven Therapy That Is Predictive of Response
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Metastatic (EGFR- and ALK-Negative/Unknown) NSCLC Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Joshua Dawkins, M.Pharmacol., PhD

Joshua Dawkins, , is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Dawkins obtained his doctorate in molecular biology at the Barts Cancer Institute, Queen Mary University of London, where he investigated the roles of epigenetic histone modifiers in pancreatic ductal adenocarcinoma. Dr. Dawkins also holds a Master of Pharmacology degree awarded by the University of Bath, and completed a one-year professional placement within the oncology team at MedImmune.


Related Reports

Non-Small-Cell Lung Cancer | Unmet Need | Detailed, Expanded Analysis: EGFR-positive metastatic non-squamous NSCLC (US & EU)

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung can...

View Details

Non-Small-Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint i...

View Details

Non-Small-Cell Lung Cancer | Geographic Focus: China | Non-Small-Cell Lung Cancer | China In-Depth | China

MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of...

View Details

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU)

MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, wh...

View Details